Clinical trials involving the editing of genes in sperm, eggs and early-stage embryos could be permitted under certain conditions, the National Academies of Sciences and the National Academy of Medicine recommended Tuesday in a long-awaited report. Once technical questions are resolved, clinical trials could start with extensive oversight, the report said. But the report urged limiting trials to the “most compelling circumstances,”...

Source: Wall Street Journal February 14, 2017 22:54 UTC